Cytisine parameters measured in the 1.5 Tesla magnetic field
DOI:
https://doi.org/10.15584/ejcem.2020.1.3Keywords:
cytisine, desmoxan, magnetic resonance imaging, tabexAbstract
Introduction. Cytisine, Cytisinum (C11H14N2O), is an organic chemical compound. Cytisine is heterotricyclic compound that is the toxic principle in Laburnum seeds and is found in many members of the Fabaceae (legume, pea or bean) family.
Aim. The aim of the study is to measure the influence of water on the form of drug in the magnetic field 1.5 Tesla.
Material and methods. For this purpose, magnetic resonance imaging tests were performed to check the solubility of pure cytisine, Desmoxan tablets and Tabex capsules.
Results. From a pharmacological point of view, both Desmoxan tablets and Tabex capsules should exert the same effect on the human body, this is due to the identical content of the active substance, in this case cytisine (1.5 mg).
Conclusion. The differences in the results obtained may be related to additional excipients that contain medications, but it is believed that they should not have a negative impact on the action of the active substance.
Downloads
References
Ostrovskaia TP. Results of clinical investigation of anti-nicotine drug patches. Med Tekh. 1994;3:42–43.
Zatonski W, Cedzynska M, Tutka P, West R. An uncontrolled trial of cytisine (Tabex) for smoking cessation. Tob Control. 2006;15:481–484.
West R, Zatonski W, Cedzynska M, et al. Placebo-controlled trial of cytisine for smoking cessation. N Engl J Med. 2011;365:1193–1200.
Walker N, Howe C, Glover M, et al. Cytisine versus nicotine for smoking cessation. N Engl J Med. 2014;371:2353–2362.
Xu WT, Li TZ, Li SM, et al. Cytisine exerts anti-tumour effects on lung cancer cells by modulating reactive oxygen species-mediated signalling pathways. Artif Cells Nanomed Biotechnol. 2020;48:84–95.
Ramotowski B, Gurbel PA, Tantry U, et al. Effect of Smoking Cessation on the Pharmacokinetics and Pharmacodynamics of Clopidogrel after PCI: The Smoking Cessation Paradox Study. Thromb Haemost. 2020. doi: 10.1055/s-0039-3402758.
Engelmann JM, Karam-Hage M, Rabius VA, Robinson JD, Cinciripini PM. 24 - Nicotine Dependence: Current Treatments and Future Directions. Abeloff's Clinical Oncology (Sixth Edition). 2020;399–410.
Hone AJ, Rueda-Ruzafa L, Gordon TJ, et al. Expression of α3β2β4 nicotinic acetylcholine receptors by rat adrenal chromaffin cells determined using novel conopeptide antagonists. Journal of Neurochemistry. 2020:e14966.
Thomas D, Farrell M, McRobbie H, et al. The effectiveness, safety and cost‐effectiveness of cytisine versus varenicline for smoking cessation in an Australian population: a study protocol for a randomized controlled non‐inferiority trial. Addiction. 2019;114:923–933.
Jeong SH, Sheridan J, Bullen C, Newcombe D, Walker N, Tingle M. Ascending single dose pharmacokinetics of cytisine in healthy adult smokers. Xenobiotica. 2019;49:1332–1337.
Huang X, Xu H. Advances on the Bioactivities, Total Synthesis, Structural Modification, and Structure-Activity Relationship of Cytisine Derivatives. Mini Rev Med Chem. 2019. doi: 10.2174/1389557519666191104121821.
Gendy MNS, Ibrahim C, Sloan ME, Le Foll B. Randomized Clinical Trials Investigating Innovative Interventions for Smoking Cessation in the Last Decade. Handb Exp Pharmacol. 2019. doi: 10.1007/164_2019_253.
Zeng L, Yu X, Yu T, Xiao J, Huang Y. Interventions for smoking cessation in people diagnosed with lung cancer. Cochrane Database Syst Rev. 2019;6:CD011751.
García-Gómez L, Hernández-Pérez A, Noé-Díaz V, Riesco-Miranda JA, Jiménez-Ruiz C. Smoking Cessation Treatments: Current Psychological and Pharmacological Options. Rev Invest Clin. 2019;71:7–16.
Duncan MS, Freiberg MS, Greevy RA, Kundu S, Vasan RS, Tindle HA. Association of Smoking Cessation With Subsequent Risk of Cardiovascular Disease. JAMA. 2019;322(7):642–650.
Hsieh MT, Tseng PT, Wu YC, et al. Effects of different pharmacologic smoking cessation treatments on body weight changes and success rates in patients with nicotine dependence: A network meta‐analysis. Obes Rev. 2019;20:895–905.
Karnieg T, Pharm D, Wang X, Pharm D. Cytisine for smoking cessation. CMAJ. 2018;190:E596.
Boido CC, Tasso B, Boido V, Sparatore F. Cytisine derivatives as ligands for neuronal nicotine receptors and with various pharmacological activities. Farmaco. 2003;58,265–277.
Gonzales D. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: A randomized controlled trial. JAMA. 2006;296:47–55.
Jeong SH, Newcombe D, Sherida J, Tingle M. Pharmacokinetics of cytisine, an α4β2 nicotinic receptor partial agonist, in healthy smokers following a single dose. Drug testing and analysis. 2015;7:475–482.
Ng M, Freeman MK, Fleming TD, et al. Smoking prevalence and cigarette consumption in 187 countries, 1980-2012. JAMA. 2014;311: 183–192.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
